



**ADDENDUM No. 2 TO THE  
MEMORANDUM OF UNDERSTANDING  
BETWEEN  
THE INDIAN COUNCIL OF MEDICAL RESEARCH, REPUBLIC OF INDIA  
AND  
THE NATIONAL INSTITUTE OF HEALTH AND MEDICAL RESEARCH,  
FRENCH REPUBLIC**

The Addendum No. 2 to the Memorandum of Understanding between the Indian Council of Medical Research (ICMR), India, and the Institut National de la Santé et de la Recherche Médicale (Inserm), France, builds upon the MoU originally signed on 10 March 2018 and renewed in 2022. The addendum reflects the mutual intent of both Parties to continue and strengthen scientific cooperation based on the successful progress achieved so far.

1. Purpose: The purpose of this addendum is to amend Articles 1, 2, and 9 of the existing MoU. The MoU is extended until March 10<sup>th</sup>, 2030. For the period 2026–2030, the Parties agree to place a specific scientific focus on metabolic disorders, while allowing inclusion of other areas of mutual interest subject to joint discussion and agreement.
2. Modes of Cooperation: Cooperation will be primarily implemented through joint research projects supported via jointly launched calls for proposals, subject to the availability of resources on both sides. The Parties will jointly determine the scope and modalities of each call, including thematic focus, timelines, number of projects, financial support, and project duration.
3. For the period 2026–2030, provisions under Articles 2.2 and 2.3 of the earlier MoU are deleted, and remaining clauses are renumbered accordingly. In addition, other collaborative actions may be undertaken based on scientific importance, mutual interest, and alignment with the objectives of the MoU.
4. This addendum shall enter into effect on 18 February 2026 and shall remain valid for the duration of the MoU. All other provisions of the original MoU that are not expressly modified by this addendum shall remain unchanged and in full effect.

Signed in two original copies.

**For ICMR**

**Dr. Rajiv Bahl**  
Secretary DHR & Director General, ICMR

**For Inserm**

**Pr. Didier SAMUEL**  
Chairman and CEO